Table 3.

Baseline characteristics and previous treatments in PS patients receiving subsequent platinum by BRCA mutation.

	Mutant	WT/VUS	p
	n = 35	n = 39
Age at diagnosis (years), Median [IQR]	59.7 [53.5; 65.7]	61.2 [56.5; 70.6]	0.155
Histology, n (%):			0.117
HGSOC	35 (100.0%)	35 (89.7%)
HGEOC	0 (0.0%)	4 (10.3%)
Pt-based chemo immediately previous to PARPi, n (%):			0.245
Pt monotherapy	5 (14.3%)	2 (5.1%)
Pt doublet	30 (85.7%)	37 (94.9%)
Months from last cycle of prior Pt to initiation of Pt immediatly pre-PARPi, n (%):			0.553
6–12 m	13 (37.1%)	18 (46.2%)
>12 m	21 (60.0%)	21 (53.8%)
Non-available	1 (2.9%)	0 (0.0%)
Number of previous lines to PARPi (including the immediately previous), Median [IQR]	2.0 [2.0; 3.0]	2.0 [2.0; 3.0]	0.493
Number of previous lines to PARPi (including the immediately previous), n (%):			0.423
=2	23 (65.7%)	21 (53.8%)
>2	12 (34.3%)	18 (46.2%)
Number of cycles of Pt-based chemo immediately previous to PARPi, Median [IQR]	6.0 [6.0; 6.0]	6.0 [5.0; 6.0]	0.477
Best response to Pt-based chemo immediately previous to PARPi, n (%):			0.579
CR	10 (28.6%)	8 (20.5%)
PR	22 (62.9%)	29 (74.4%)
SD	3 (8.6%)	2 (5.1%)
Months with Pt-based CT treatment, Median [IQR]	4.7 [4.0; 5.8]	4.2 [3.3; 5.3]	0.055
PARPi, n (%):			<0.001
olaparib	33 (94.3%)	7 (17.9%)
niraparib	2 (5.7%)	31 (79.5%)
rucaparib	0 (0.0%)	1 (2.6%)
Months with PARPi, Median [IQR]	11.9 [8.2; 20.7]	8.3 [5.8; 12.7]	0.007
Prior PARPi, n (%):			1.000
No	32 (100.0%)	36 (97.3%)
maybe	0 (0.0%)	1 (2.7%)
Months from finishing Pt pre-PARPi to Pt pre-PARPi progression, Median (PFI) [IQR]	13.6 [11.2; 22.2]	10.3 [7.4; 14.9]	0.010
Months from PARPi initiation to Pt pre-PARPi progression, Median (PFI-PARPi) [IQR]	12.2 [9.1; 20.0]	8.3 [5.7; 12.7]	0.006

Pt: platinum.